New trial seeks to improve survival rates for patients with COVID-19
A new trial is taking place at Addenbrooke’s Hospital to test whether COVID-19 patients with weak immune systems have a better chance of survival if they are injected with plasma from people who have successfully recovered from the virus.
The trial will examine whether antibody rich plasma, known as ‘convalescent plasma’ can be given to people who are struggling to develop an immune response to the illness. Scientists want to discover whether this treatment would improve a COVID-19 patient’s speed of recovery and chances of survival.
The clinical trial is being run nationally by NHS Blood and Transplant (NHSBT). Although there is some evidence of patient benefit, it will seek to confirm the safety and effectiveness of convalescent plasma transfusions. If successful, the plasma has the added benefit of being freezable, so donations can be stockpiled ahead of a potential second wave.
For more information visit: CUH News
Published June 8, 2020
Latest from CCTU
Targeting the immune system could prevent future heart attacks, Cambridge-led trial suggests
Cambridge researchers have discovered that an existing therapy which boosts protective immune cells in people who have recently had heart attacks reduces…
Cambridge study finds hot flush treatment has anti-breast cancer activity
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast…
Innovative trial offers hope on World Pancreatic Cancer Day
An early-stage trial, recently opened at Addenbrooke's Hospital, offers new hope to people with late-stage pancreatic cancer and their families.
…
